We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bryophyllum vs. Nifedipine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by Weleda AG.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00391339
First Posted: October 23, 2006
Last Update Posted: October 23, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Weleda AG
  Purpose
In a prospective, randomised study the efficacy and tolerability of bryophyllum p. (p.o) vs. nifedipine (p.o) will be proofed in a defined group of pregnant women with threatened preterm labour.

Condition Intervention Phase
Tocolysis Drug: Bryophyllum p. Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions

Resource links provided by NLM:


Further study details as provided by Weleda AG:

Estimated Enrollment: 140
Study Start Date: November 2006
Estimated Study Completion Date: October 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female

Exclusion Criteria:

  • Bishop Score > 5
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00391339


Locations
Switzerland
Department of Obstetrics, University of Zuerich Not yet recruiting
Zuerich, Switzerland, 8091
Principal Investigator: Roland Zimmermann, Prof. Dr. med.         
Principal Investigator: Ursula von Mandach, Prof. Dr. pharm.         
Sponsors and Collaborators
Weleda AG
Investigators
Principal Investigator: Roland Zimmermann, Prof. Dr. med. Department of Obstetrics, University Zuerich
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00391339     History of Changes
Other Study ID Numbers: CI-C-64-Wel-06
First Submitted: October 19, 2006
First Posted: October 23, 2006
Last Update Posted: October 23, 2006
Last Verified: October 2006

Keywords provided by Weleda AG:
Bryophyllum p.
Nifedipine
Tocolysis

Additional relevant MeSH terms:
Nifedipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs